Association between colorectal cancer and the degree of ITGA4 promoter methylation in peripheral blood mononuclear cells

Jafarpour, Sima; Saberi, Farideh; Yazdi, Maryam; Amini, Gilda; Ferns, Gordon A.; Salehi, Roya

doi:10.1016/j.genrep.2022.101580

Cited by 5 publications

(3 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 20 ] We demonstrated the accuracy, reliability, and high quality of MethyQESD for methylation analysis in the PBMCs of CRC patients in agreement with previous studies. [ 29 30 31 32 ] In this regard, Bagheri et al . [ 29 ] revealed that the methylation status of TFPI2 and NDRG4 genes in PBMCs has high sensitivity and specificity for the detection of CRC, and the combination of these genes provides sufficiently higher diagnostic power (AUC = 0.961), suggesting a promising noninvasive CRC screening approach.…”

Section: Discussionmentioning

confidence: 99%

Hypermethylation of MGMT Gene Promoter in Peripheral Blood Mononuclear Cells as a Noninvasive Biomarker for Colorectal Cancer Diagnosis

Azhdari,

Khodabandehloo,

Ehtesham

et al. 2023

Advanced Biomedical Research

View full text Add to dashboard Cite

Background: Early colorectal cancer (CRC) diagnosis can drastically reduce CRC-related morbidity and mortality. In this regard, increasing attention is now being directed to DNA-based tests, especially the evaluation of methylation levels, to prioritize high-risk suspected persons for colonoscopy examination. Therefore, we aimed to assess the accuracy of MGMT gene promoter methylation levels in peripheral blood mononuclear cells (PBMCs) for distinguishing CRC patients from healthy people. Materials and Methods: For this study, a total of seventy individuals with CRC and 75 healthy individuals from Iran were included. The methylation level of MGMT in the DNA isolated from PBMCs was evaluated using the methylation quantification endonuclease-resistant DNA technique. To assess the diagnostic capability of the MGMT promoter methylation level, a receiver operating characteristic (ROC) curve was generated. Results: The mean promoter methylation level of MGMT in the CRC and control groups was, respectively, 27.83 ± 22.80 vs. 12.36 ± 14.48. The average percentage of methylation of the MGMT promoter between the CRC and control groups was significantly different (P < 0.001). Also, the MGMT promoter was more hypermethylated in female patients than in males. ROC analyses indicated that the diagnostic power of the MGMT promoter methylation level for CRC was 0.754, with a sensitivity of 81.43% and a specificity of 75.71%, indicating a good biomarker for CRC diagnosis. Conclusion: Methylation evaluation of MGMT in PBMCs could be utilized as a diagnostic biomarker with high accuracy for prioritizing suspected CRC patients before colonoscopy.

show abstract

Section: Discussionmentioning

confidence: 99%

Hypermethylation of MGMT Gene Promoter in Peripheral Blood Mononuclear Cells as a Noninvasive Biomarker for Colorectal Cancer Diagnosis

Azhdari,

Khodabandehloo,

Ehtesham

et al. 2023

Advanced Biomedical Research

View full text Add to dashboard Cite

show abstract

“…These studies confirmed that hypo- or hyper-methylation of these loci in blood leukocytes and PBMCs can be used as biomarkers for diagnosis and prognosis in different types of malignancies including head and neck, gastric, testicular, bladder, colon, liver, lung, nasopharynx, breast, and renal cell cancer. [ 28 29 30 31 32 33 34 35 ] On the other hand, subsequent studies focused on methylation assessment of specific promoter genes in blood cells, which led to the introduction of promising biomarkers such as IGF2 in gastric and colorectal cancer;[ 36 ] CDH1 in hereditary diffuse gastric cancer;[ 37 ] MMP9, TFPI2, NDRG4, SDC2 , and ITGA4 in CRC;[ 6 7 9 38 ] NEUROD1, NUP155, SFRP1, TITF1 , and ATM in breast cancer;[ 39 40 41 ] P53, CSF3R , and ERCC1 in lung cancer;[ 42 43 ] and IL10, LCN2, AIM2, TAL1 , and ZAP70 in pancreatic cancer. [ 44 ] Regarding this evidence as well as a hypothesis about possible connections between PBMCs and released exosomes from cancer cells, the reflection of the epigenetic status of tumor cells in PBMCs has made them a novel source of biomarkers.…”

Section: Discussionmentioning

confidence: 99%

“…[ 5 ] Several studies have reported methylation alterations of LINE-1 sequence and promoters of MMP9, IFNG, TFPI2, NDRG4, ITGA4 , and BRCA1 genes in a variety of cancers. [ 6 7 8 9 ] The exact molecular mechanisms underlying DNA methylation changes in PBMCs have not yet been determined. However, one assumption is that PBMCs, as surrogate cells, can mimic the status of neighboring tissues such as cancer cells.…”

Section: Introductionmentioning

confidence: 99%

TUSC3 methylation in peripheral blood cells as a biomarker for diagnosis of colorectal cancer

et al. 2023

View full text Add to dashboard Cite

Background: Several case-control studies have suggested that global and loci-specific deoxyribonucleic acid (DNA) methylation in peripheral blood mononuclear cells (PBMCs) of DNA might be potential biomarkers of cancer diagnosis and prognosis. In this study, for the first time, we intended to assess the diagnostic power of the methylation level of tumor suppressor candidate 3 ( TUSC3 ) gene promoter in patients with colorectal cancer (CRC). Materials and Methods: In the current study, we quantitatively assessed the promoter methylation level of TUSC3 in PBMCs of 70 CRC cases and 75 non-cancerous subjects via methylation quantification of endonuclease-resistant DNA (MethyQESD) method. Results: The methylation level of the TUSC3 was meaningfully higher in CRC cases than in non-CRC subjects (43.55 ± 21.80% vs. 16.07 ± 13.63%, respectively; P < 0.001). The sensitivity and specificity of this gene for the detection of CRC were 88.6% and 76.0%, respectively. The receiver operating characteristic (ROC) curve examination discovered an area under the curve (AUC) of 0.880, representing a very high accuracy of the TUSC3 methylation marker in distinguishing CRC subjects from healthy individuals. However, there was no substantial diversity in methylation level between various CRC stages ( P : 0.088). Conclusion: For CRC screening, PBMCs are a reliable source for DNA methylation analysis and TUSC3 promoter methylation can be utilized as a hopeful biomarker for early and non-invasive diagnosis of CRC.

show abstract

Epigenetic and metabolic reprogramming in inflammatory bowel diseases: diagnostic and prognostic biomarkers in colorectal cancer

Deris Zayeri,

Parsi,

Shahrabi

et al. 2023

Cancer Cell Int

View full text Add to dashboard Cite

Background and aim "Inflammatory bowel disease" (IBD) is a chronic, relapsing inflammatory disease of the intestinal tract that typically begins at a young age and might transit to colorectal cancer (CRC). In this manuscript, we discussed the epigenetic and metabolic change to present a extensive view of IBDs transition to CRC. This study discusses the possible biomarkers for evaluating the condition of IBDs patients, especially before the transition to CRC. Research approach We searched “PubMed” and “Google Scholar” using the keywords from 2000 to 2022. Discussion In this manuscript, interesting titles associated with IBD and CRC are discussed to present a broad view regarding the epigenetic and metabolic reprogramming and the biomarkers. Conclusion Epigenetics can be the main reason in IBD transition to CRC, and Hypermethylation of several genes, such as VIM, OSM4, SEPT9, GATA4 and GATA5, NDRG4, BMP3, ITGA4 and plus hypomethylation of LINE1 can be used in IBD and CRC management. Epigenetic, metabolisms and microbiome-derived biomarkers, such as Linoleic acid and 12 hydroxy 8,10-octadecadienoic acid, Serum M2-pyruvate kinase and Six metabolic genes (NAT2, XDH, GPX3, AKR1C4, SPHK and ADCY5) expression are valuable biomarkers for early detection and transition to CRC condition. Some miRs, such as miR-31, miR-139-5p, miR -155, miR-17, miR-223, miR-370-3p, miR-31, miR -106a, miR -135b and miR-320 can be used as biomarkers to estimate IBD transition to CRC condition.

show abstract

Association between colorectal cancer and the degree of ITGA4 promoter methylation in peripheral blood mononuclear cells

Cited by 5 publications

References 60 publications

Hypermethylation of MGMT Gene Promoter in Peripheral Blood Mononuclear Cells as a Noninvasive Biomarker for Colorectal Cancer Diagnosis

Hypermethylation of MGMT Gene Promoter in Peripheral Blood Mononuclear Cells as a Noninvasive Biomarker for Colorectal Cancer Diagnosis

TUSC3 methylation in peripheral blood cells as a biomarker for diagnosis of colorectal cancer

Epigenetic and metabolic reprogramming in inflammatory bowel diseases: diagnostic and prognostic biomarkers in colorectal cancer

Contact Info

Product

Resources

About